Search bioRxiv⌕ Search

Biology subjects

Grillo, A. S.

Publications and source records attributed to Grillo, A. S..

4 recordsLinked to original sources

Reactive Oxygen Species Generation Drives Iron Accumulation by Rotenone-Mediated Inhibition of Mitochondrial Complex I in Dopaminergic Neurons

Iron is an essential element that plays a critical role in mitochondrial bioenergetics, yet its excess is cytotoxic and contributes to the development of neurodegenerative diseases such as Parkinsons disease (PD). Impaired Complex I (CI) activity, which can be caused by exposure to the environmental toxin rotenone, is implicated in PD. The mechanistic underpinnings connecting iron dyshomeostasis to cytotoxicity remain unclear, which creates challenges towards preventing neuronal cell death in PD. We hypothesized that CI inhibition is sufficient to disrupt cellular iron homeostasis via reactive oxygen species (ROS) generation. Using SH-SY5Y cells differentiated into dopaminergic neurons, we show that rotenone-induced CI inhibition increases ROS, promotes oxidative stress and cytotoxicity, and drives a redistribution of labile iron. Specifically, mitochondrial and total cellular iron levels increase, while cytosolic labile iron is reduced. Antioxidant treatment blocks both ROS production and iron accumulation, suggesting that ROS is critical for iron maldistribution in our system. Conversely, iron chelation suppresses ROS propagation, suggesting a positive feedback loop in which iron further amplifies oxidative stress. Our data are consistent with a greater sensitivity of mitochondrial [4Fe-4S]-containing proteins relative to the [2Fe-2S] proteins examined, potentially contributing to mitochondrial iron retention. Together, these findings establish a mechanistic link between mitochondrial dysfunction and iron dyshomeostasis and offer insights into how environmental CI inhibitors contribute to the pathogenesis of PD. More broadly, this work may have relevance to sporadic PD and other genetic or age-related disorders associated with iron accumulation and mitochondrial diseases such as Leigh Syndrome.

biochemistry↗

Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh Syndrome

Mitochondrial diseases represent a spectrum of disorders caused by impaired mitochondrial function ranging in severity from mortality during infancy to progressive adult-onset disease. Mitochondrial dysfunction is also recognized as a molecular hallmark of the biological aging process. Rapamycin, a drug that increases lifespan and health during normative aging also increases survival and reduces neurological symptoms in a mouse model of the severe mitochondrial disease Leigh Syndrome. The Ndufs4 knockout (Ndufs4-/-) mouse lacks the complex I subunit NDUFS4 and shows rapid onset and progression of neurodegeneration mimicking patients with Leigh Syndrome. Here we show that another drug that extends lifespan and delays normative aging in mice, acarbose, also suppresses symptoms of disease and improves survival of Ndufs4-/- mice. Unlike rapamycin, acarbose rescues disease phenotypes independently of mTOR inhibition. Furthermore, rapamycin and acarbose have additive effects in delaying neurological symptoms and increasing maximum lifespan in Ndufs4-/- mice. We find that acarbose remodels the intestinal microbiome and alters the production of short chain fatty acids. Supplementation with tributyrin, a source of butyric acid, recapitulates some effects of acarbose on lifespan and disease progression. This study provides the first evidence that alteration of the gut microbiome may impact severe mitochondrial disease and provides further support for the model that biological aging and severe mitochondrial disorders share underlying common mechanisms.

biochemistry↗

Iron Status Influences Mitochondrial Disease Progression in Complex I-Deficient Mice

Mitochondrial dysfunction caused by aberrant Complex I assembly and reduced activity of the electron transport chain is pathogenic in many genetic and age-related diseases. Mice missing the Complex I subunit NADH dehydrogenase [ubiquinone] iron-sulfur protein 4 (NDUFS4) are a leading mammalian model of severe mitochondrial disease that exhibit many characteristic symptoms of Leigh Syndrome including oxidative stress, neuroinflammation, brain lesions, and premature death. NDUFS4 knockout mice have decreased expression of nearly every Complex I subunit. As Complex I normally contains at least 8 iron-sulfur clusters and more than 25 iron atoms, we asked whether a deficiency of Complex I may lead to intracellular iron perturbations thereby accelerating disease progression. Consistent with this, iron supplementation accelerates symptoms of brain degeneration in these mice while iron restriction delays the onset of these symptoms and increases survival. NDUFS4 knockout mice display signs of iron overload in the liver including increased expression of hepcidin, and show changes in iron responsive element-regulated proteins consistent with increased intracellular iron that were prevented by iron restriction. These results suggest that perturbed iron homeostasis may contribute to pathology in Leigh Syndrome and possibly other mitochondrial disorders.

molecular biology↗

Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin

Leigh syndrome is a fatal neurometabolic disorder caused by defects in mitochondrial function. mTOR inhibition with rapamycin attenuates disease progression in a mouse model of Leigh syndrome (Ndufs4 KO mouse); however, the mechanism of rescue is unknown. Here we assessed the impact of rapamycin on the brain proteome and phosphoproteome of Ndufs4 KO mice. We report that rapamycin remodels the brain proteome to alter mitochondrial structure, inhibits signaling through both mTOR complexes, and inhibits multiple protein kinase C (PKC) isoforms. Administration of PKC inhibitors was sufficient to increase survival, delay neurological deficits, and prevent hair loss in Ndufs4 KO mice. Thus, PKC may be a viable therapeutic target for treating severe mitochondrial disease. One Sentence SummaryProteomic and phosphoproteomic analysis of mouse brain identifies PKC as a key target to treat mitochondrial disease

neuroscience↗